This review is devoted to analyses of data on efficacy and safety of desloratadine in chronic urticaria therapy.
В обзоре обобщены литературные данные об эффективности и безопасности дезлоратадина в терапии хронической крапивницы.
desloratadinetherapyH-blockerschronic urticariaдезлоратадинантигистаминная терапияблокаторы Н-гистаминовых рецепторовхроническая крапивницаSanchez-Borges M., Asero R., Ansotegui I.J. et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ. J. 2012, v. 5, p. 125-147.Zuberbier T., Aberer W., Asero R. et al. The EAACI/GA2LEN/ EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69, p. 868-887.O’Donnell B.F., Lawlor F., Simpson J. et al. The impact of chronic urticaria on the quality of life. Br. J. Dermatol. 1997, v. 136, p. 197-201.Горячкина Л.А., Ненашева Н.М., Борзова Е.Ю. Крапивница. Леч. врач. Дерматовенерология. 2003, № 9, с. 10-4.Simons F.E.R., Akdis C.A. Histamine and antihistamines. Middleton’s Allergy Principles and Practice, 7th edn. Ed. by N.F. Adkinson Jr., WW Busse et al. St. Louis: Mosby Inc. (an affiliate of Elsevier Science). 2008, p. 1517-1547.Akdis C.A., Simons F.E.R. Histamine receptors are hot in immunopharmacology. Eur. J. Pharmacol. 2006, v. 533, p. 69-76.Akdis C.A., Jutel M., Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem. Immunol. Allergy. 2008, v. 94, p. 67-82.Schneider E., Rolli-Derkinderen M., Arock M., Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. 2002, v. 23, p. 255-263.Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, c. 252.Zuberbier T., Aberer W, Asero R. et al. The EAACI/GA2LEN/ EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69 (7), p. 868-887.Simons F.E.R. Advances in Hj-antihistamines. N. Engl. J. Med. 2004, v. 351, р. 2203-2217.Holgate S.T., Canonica G.W., Simons F.E. et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clinical & Experimental Allergy. 2003, v. 33, p. 1305-1324.Kreutner W., Hey J.A., Anthes J. et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine Hj-receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung. 2000, v. 50, p. 345-352.Anthes J.C., Gilchrest H., Richard C. et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1-receptor. Eur. J. Pharmacol. 2002, v. 449, p. 229-237.DuBuske L.M. Pharmacology of Desloratadine. Special Characteristics Clin. Drug Invest. 2002, v. 22, p. 1-11.Wu R.L., Anthes J.C., Kreutner W et al. Desloratadineinhibits constitutive and histamine-stimulated nuclear factor-KB ac tivity consistent with inverse agonism at the histamine Hj-re-ceptor. Int. Arch. Allergy Immunol. 2004, v. 135, p. 313-318.Schroeder J.T., Schleimer R.P., Lichtenstein L.M. et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Exp. Allergy. 2001, v. 31, p. 1369-1377.Agrawal D.K. Antiinflammatory properties of desloratadine. Clin. Exp. Allergy. 2004, v. 34, p. 1342-1348.Weller K., Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. J. Invest Dermatol. 2009, v. 129, p. 2723-2726.Canonica G.W., Blaiss M. Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: A Review of the Evidence. World Allergy Organ J. 2011, v. 4, p. 47-53.Bakker R.A., Schoonus S.B.J., Smit M.J. et al. Histamine Hj-receptor activation of nuclear factor-KB: roles for Gβγ and Gα(q/11)-subunits in constitutive and agonist-mediated signaling. Mol. Pharmacol. 2001, v. 60, p. 1133-1142.DuBuske L. Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am. J. Clin. Dermatol. 2007, v. 8, p. 271-283.Ring J., Hein R., Gauger A. et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int. J. Dermatol. 2001, v. 40, p. 72-76.Lachapelle J.M., Decroix J., Henrijean A. et al. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. J. Eur. Acad. Dermatol. Venereol. 2006, v. 20, p. 288-292.Grob J.J., Auquier P., Dreyfus I., Ortonne J.P. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009, v. 64, p. 605-612.Augustin M., Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of9246 patients. J. Eur. Acad. Dermatol. Venereol. 2009, v. 23, p. 292-299.DuBuske L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopaticurticaria and allergic inflammatory disorders. Expert Opin. Pharmacother. 2005, v. 6, p. 2511-2523.Леонова М.В. Современные антигистаминные препараты: выбор в изобилии предложений. Фарматека. 2011, № 10, с. 26-32.Ozdemir P.G., Karadag A.S., Selvi Y. al. Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness and dream anxiety. Int. J. Psychiatry Clin. Pract. 2014, v. 18, p. 161-168.